Molecular and Cellular Biochemistry

, Volume 348, Issue 1–2, pp 21–32 | Cite as

Beneficial effect of insulin in hyperhomocysteinemia and diabetes mellitus-induced vascular endothelium dysfunction: role of phosphoinositide dependent kinase and protein kinase B

  • Saurabh Sharma
  • Manjeet Singh
  • Pyare Lal Sharma


A primary defect in the vascular action of insulin may be the key intermediate mechanism that links endothelial dysfunction with diabetes mellitus and hyperhomocysteinemia. This study investigated the downstream targets of insulin, involved in this process. Hyperhomocysteinemia (serum homocysteine > 10 μm/l) was produced in rats by administering l-methionine (1.7% w/w, p.o.x. 4 weeks) and diabetes mellitus (serum glucose > 140 mg/dl) was induced using streptozotocin (55 mg/kg/day, i.v. once) in another group. Four weeks after l-methionine and streptozotocin administration, vascular endothelium dysfunction was assessed in terms of attenuation of acetylcholine-induced, endothelium-dependent relaxation (isolated aortic ring preparation), decrease in serum nitrate/nitrite level, as well as mRNA expression of eNOS (rtPCR), and disruption of integrity of vascular endothelium. Both hyperhomocysteinemia and diabetes mellitus significantly attenuated acetylcholine-induced endothelial-dependent relaxation, and the increase in serum nitrite/nitrate concentration and the expression of eNOS. Insulin (0.4 and 0.6 IU/kg/day, s.c.) and atorvastatin (30 mg/kg/day, p.o.x. 4 weeks) significantly improved all these parameters. However, this ameliorative effect of insulin was blocked by 7-hydroxystaurosporine (UCN-01) [Inhibitor of phosphoinositide dependent kinase (PDK)], and triciribine (API-2) (protein kinase B/Akt inhibitor). It is suggested that amelioration of vascular endothelium dysfunction by insulin may be due to stimulation of PDK and Akt pathways.


Vascular endothelium dysfunction Phosphoinositide dependent kinase Endothelial nitric oxide synthatase Diabetes mellitus Hyperhomocysteinemia 



This article is dedicated to the fond memory of Prof. Manjeet Singh who expired on 30 Mar 2009, while this study was in progress. We gratefully acknowledge the assistance and advice received from the All India Institute of Medical Sciences, New Delhi, and from Mr. Vivek Sharma of Punjabi University Patiala for electron microscopy and rt PCR of mRNA of eNOS respectively. We are grateful to Mr. Praveen Garg, The Chairman, ISFCOP, Moga for his support and encouragement during the conduct of this study.


  1. 1.
    Rask-Madsen C, King GL (2007) Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 3(1):46–56CrossRefPubMedGoogle Scholar
  2. 2.
    Guilliams T (2004) Homocysteine—a risk factor for vascular diseases: guidelines for the clinical practice. JANA 7(1):11–24Google Scholar
  3. 3.
    Shah DI, Singh M (2007) Possible role of Akt to improve vascular endothelium dysfunction in diabetic and hyperhomocysteinemic rats. Mol Cell Biochem 295:65–74CrossRefPubMedGoogle Scholar
  4. 4.
    Nakagami H, Kaneda Y, Ogihara T, Morishita R (2005) Endothelial dysfunction in hyperglycemia as a trigger of atherosclerosis. Curr Diabetes Rev 1:59–63CrossRefPubMedGoogle Scholar
  5. 5.
    Pieper GM, Langenstroer P, Siebeneich W (1997) Diabetic induced endothelial dysfunction in rat aorta: role of hydroxyl radical’s. Cardiovasc Res 37:145–156CrossRefGoogle Scholar
  6. 6.
    Esper RJ, Roberto AN, Jorge OV, Antonio P, José LC, Rogelio AM (2006) Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol 5:4CrossRefPubMedGoogle Scholar
  7. 7.
    McDowell IFW, Lang D (2000) Homocysteine and endothelial dysfunction: a link with cardiovascular disease. J Nutr 130:369S–372SPubMedGoogle Scholar
  8. 8.
    Ueland PM, Refsum H, Beresford SA, Vollset SE (2000) The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 72:324–332PubMedGoogle Scholar
  9. 9.
    Dudzinski DM, Michel T (2007) Life history of eNOS: partners and pathways. Cardiovasc Res 75:247–260CrossRefPubMedGoogle Scholar
  10. 10.
    Endemann HD, Ernesto LS (2004) Endothelial dysfunction. J Am Soc Nephrol 15:1983–1992CrossRefPubMedGoogle Scholar
  11. 11.
    Alfonso M, David K, Daan MF, Van A, Dario R (2004) PDK1, the master regulator of AGC kinase signal transduction. Semin Cell Dev Biol 15:161–170CrossRefGoogle Scholar
  12. 12.
    Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse RP, Zeiher AM (1999) Activation of nitric oxide synthase in endothelial cells by Akt dependent phosphorylation. Nature 399:601–605CrossRefPubMedGoogle Scholar
  13. 13.
    Ramm G, Larance M, Guilhaus M, James DE (2006) A role for 14–3-3 in insulin-stimulated GLUT4 translocation through its interaction with the Rab GAP AS160. J Biol Chem 281:29174–29180CrossRefPubMedGoogle Scholar
  14. 14.
    Dimmeler S, Aicher A, Vasa M et al (2001) HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 108:391–397PubMedGoogle Scholar
  15. 15.
    Shah DI, Singh M (2007) Effect of demethylasteroquinone B1 in hypertension associated vascular endothelial dysfunction. Int J Cardiol 120:317–324CrossRefPubMedGoogle Scholar
  16. 16.
    Cleland SJ, Petrie JR, Small M, Elliott HL, Connell JM (2000) Insulin action is associated with endothelial function in hypertension and type 2 diabetes. Hypertension 35:507–511PubMedGoogle Scholar
  17. 17.
    Eliana HA, Elisa Mk, Cristoforo S, Dorthy N, Maria HC, Carvalho RCA, Tostes LR, Zuleica BF (2006) Correction of endothelial dysfunction in diabetic female rats by tetrahydrobiopterin and chronic insulin. J Vasc Res 43:309–320CrossRefGoogle Scholar
  18. 18.
    Jana Z, Ludmila K, Terezie P, Jessie NL, Sharon A, Radko K (2008) Renal activity of Akt kinas in obese Zuker rats. Exp Biol Med 233:1231–1241CrossRefGoogle Scholar
  19. 19.
    Dimitrova KR, Degroot KW, Pacqing AM, Suyderhoud JP, Pirovic EA, Munroa TJ, Wieneke JA, Myers AK, Kim YD (2002) Estradiol prevents homocysteine-induced endothelial injury in male rats. Cardiovasc Res 53:589–596CrossRefPubMedGoogle Scholar
  20. 20.
    Jacobsen DW, Gatautis VJ, Green R, Robinson K, Savon SR, Secic M, Ji J, Otto JM, Taylor LM Jr (1994) Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. Clin Chem 40(6):857–858Google Scholar
  21. 21.
    Sastry KVH, Moudgal RP, Mohan J, Tyagi JS, Rao GS (2002) Spectrophotometric determination of serum nitrite and nitrate by copper cadmium alloy. Anal Biochem 306:79–82CrossRefPubMedGoogle Scholar
  22. 22.
    Woodman LO, Melinda AM, Mirna B (2004) Daidzein and 17 β estradiol enhance nitric oxide synthatase activity associated with an increase in calmodulin and a decrease in caveolin-1. J Cardiovasc Pharmacol 44(2):155–163CrossRefPubMedGoogle Scholar
  23. 23.
    Kobayashi T, Matsumoto T, Ooishi K, Kamata K (2004) Differential expression of 2D-adrenoceptor and eNOS in aortas from early and later stages of diabetes in Goto-Kakizaki rats. Am J Physiol Heart Circ Physiol 287:H135–H143CrossRefPubMedGoogle Scholar
  24. 24.
    Schiller NK, Timothy AM, Chen IL, Rice RC, Akers DL, Kadowitz PJ, McNamaran DB (1999) Endothelial cell regrowth and morphology after balloon catheter injury of Alloxan-induced diabetic rabbits. Am J Physiol 277:240–248Google Scholar
  25. 25.
    Brownlee M (2005) The Pathobiology of diabetic complications. A unifying mechanism. Diabetes 54(6):1615–1625CrossRefPubMedGoogle Scholar
  26. 26.
    Schulz R (2005) Pleiotropic effects of Statins: Acutely good, but chronically bad? J Am Coll Cardiol 45:1292–1294CrossRefPubMedGoogle Scholar
  27. 27.
    Laufs U, Gertz K, Huang P, Nickenig G, Bohm M, Dirnagl U, Endres M (2000) Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholestrolemic mice. Stroke 31:2442–2449PubMedGoogle Scholar
  28. 28.
    Tan KCB, Chow WS, Tan SCF, Ai VHG, Lam CHL, Lam KSL (2002) Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 87:563–568CrossRefPubMedGoogle Scholar
  29. 29.
    Li H, Lewis A, Brodsky S, Rieger R, Iden C, Goligorsky MS (2002) Homocysteine induces 3-hydroxy-3-methylglutaryl coenzyme a reductase in vascular endothelial cells: a mechanism for development of atherosclerosis? Circulation 105:1037–1043CrossRefPubMedGoogle Scholar
  30. 30.
    Stuhlinger MK, Tsao PS, Her J-H, Kimoto M, Balint RF, Cooke JP (2001) Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 104:2569–2575CrossRefPubMedGoogle Scholar
  31. 31.
    Shiojima I, Walsh K (2002) Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 90:1243–1250CrossRefPubMedGoogle Scholar
  32. 32.
    Kobayashi T, Taguchi K, Nemoto S, Nogami T, Matsumoto T, Kamata K (2009) Activation of the PDK-1/Akt/eNOS pathway involved in aortic endothelial function differs between hyperinsulinemic and insulin-deficient diabetic rats. Am J Physiol Heart Circ Physiol. 297(5):H1767–H1775CrossRefPubMedGoogle Scholar
  33. 33.
    Yan TT, Li Q, Zhang XH, Wu WK, Sun J, Li L, Zhang Q, Tan HM (2010) Homocysteine impaired endothelial function via compromised VEGF/Akt/eNOS signaling. Clin Exp Pharmacol Physiol. doi: 10.1111/j.1440-1681.2010.05438.x
  34. 34.
    Sato S, Fujita N, Suruo T (2002) Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 21:1727–1738CrossRefPubMedGoogle Scholar
  35. 35.
    Yang L, Dan HC, Sun M, Liu Q, Sun MX, Feldman IR, Hamilton DA, Mark P, Nicosia SV, Herlyn M, Sebti SM, Cheng JQ (2004) Akt/Protein kinase signaling inhibitor-2, a selective molecule inhibitor of Akt signaling with antitumour activity in cancer cells overexpressing Akt. Cancer Res 64:4394–4399CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Saurabh Sharma
    • 1
  • Manjeet Singh
    • 1
  • Pyare Lal Sharma
    • 1
  1. 1.Department of PharmacologyISF College of PharmacyMogaIndia

Personalised recommendations